Claims
- 1. A method for preparing an oxazole of the structure ##STR21## wherein m is 1, 2 or 3;
- n is 0, 1, 2, 3 or 4;
- R.sup.1 is hydrogen, lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or an amide of the structure ##STR22## wherein t is 1 to 12 and Ra is lower alkyl, aryl, cycloalkyl or cycloalkylalkyl;
- R.sup.2 is hydrogen, lower alkyl, aryl, or aralkyl; or
- R.sup.1 and R.sup.2 together with the N to which they are linked form a 5- to 8-membered ring which has only the single N heteroatom, wherein the term aryl by itself or as part of another group refers to phenyl or naphthyl, or phenyl or naphthyl optionally substituted with 1 or 2 substituents which are lower alkyl, halogen, alkylsulfonyl and/or arylsulfonyl, which comprises providing an oxazoline of the structure ##STR23## treating the oxazoline with an oxidizing agent which is cupric bromide or ferric bromide, a base which is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), and a non-hydride donor amine which does not have an .alpha.H or which will not easily lose an H at the .alpha. carbon under oxidation conditions and therefore will not undergo oxidation, to convert said oxazoline to the oxazole.
- 2. The method as defined in claim 1 wherein the non-hydride donor amine is hexamethylenetetraamine (HMTA), tert-butylamine, diazabicyclooctane (DABCO) or quinuclidine.
- 3. The method as defined in claim 1 wherein R.sup.1 is hydrogen, R.sup.2 is alkyl, m is 1 and n is 2.
- 4. The method as defined in claim 1 wherein R.sup.2 is pentyl.
- 5. The method as in claim 3 wherein m is 1, n is 2, R.sup.1 is H, R.sup.2 is pentyl and CO.sub.2 alkyl is CO.sub.2 CH.sub.3.
- 6. The method as defined in claim 5 wherein the oxidizing agent is cupric bromide, the base is DBU, and the non-hydride donor amine is hexamethylenetetraamine.
- 7. The method as defined in claim 1 wherein the oxazoline has the structure ##STR24##
- 8. The method as defined in claim 1 wherein a single charge of cupric bromide, DBU and a non-hydride donor amine, which is hexamethylenetetraamine, is employed.
- 9. The method as defined in claim 1 wherein a double charge of cupric bromide, DBU and non-hydride donor amine, which is hexamethylenetetraamine, is employed.
- 10. The method as defined in claim 1 wherein the reaction is carried out in the presence of an inert organic solvent which is dichloromethane.
- 11. The method as defined in claim 1 wherein the reaction is carried out for a period within the range of from about 4 to about 24 hours.
- 12. The method as defined in claim 1 wherein the oxazole is recovered in substantially pure form.
- 13. The method as defined in claim 1 wherein the bromide is employed in a molar ratio to oxazoline within the range of from about 2.5:1 to about 5:1, the base is employed in a molar ratio to oxazoline of within the range of from about 2.5:1 to about 5:1, and the non-hydride donor amine base is employed in a molar ratio to oxazoline of within the range of from about 2.5:1 to about 5:1.
- 14. The method as defined in claim 11 wherein hexamethylenetetraamine is employed as the non-hydride donor amine and each of the cupric bromide, DBU and hexamethylenetetraamine will be employed in an amount to provide from about 3 to about 4 molar equivalents of each to each molar equivalent of oxazoline.
- 15. The method as defined in claim 14 wherein each of the cupric bromide, DBU and hexamethylenetetraamine are employed in an amount to provide about 4 molar equivalents of each to each molar equivalent of oxazoline.
- 16. The method as defined in claim 15 which is carried out for a period of from about 4 to about 6 hours.
- 17. The method as defined in claim 6 wherein each of the cupric bromide, DBU and non-hydride donor amine base will be divided into two charges and each of the first charges will be employed in amounts so as to provide a molar ratio of cupric bromide to oxazoline of within the range of from about 1.5:1 to about 2.5:1, a molar ratio of DBU to oxazoline of within the range of from about 1.5:1 to about 2.5:1, and a molar ratio of non-hydride donor amine to oxazoline of within the range of from about 1.5:1 to about 2.5:1.
- 18. The method as defined in claim 17 wherein the reaction of the oxazoline within the initial charge will be for a period within the range of from about 3 to about 10 hours, and thereafter, a second charge of each of the cupric bromide, DBU and nonhydride donor amine in amounts approximately the same as in the first charge will be added to the reaction mixture and the reaction will be continued for a period of within the range of from about 8 to about 15 hours.
- 19. A method for preparing an acid of the structure ##STR25## wherein m is 1, 2 or 3;
- n is 0, 1, 2, 3 or 4;
- R.sup.1 is hydrogen, lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or an amide of the structure ##STR26## wherein t is 1 to 12 and Ra is lower alkyl, aryl, cycloalkyl or cycloalkylalkyl;
- R.sup.2 is hydrogen, lower alkyl, aryl, or aralkyl; or
- R.sup.1 and R.sup.2 together with the N to which they are linked form a 5- to 8-membered ring which has only the single N heteroatom, wherein the term aryl by itself or as part of another group refers to phenyl or naphthyl, or phenyl or naphthyl optionally substituted with 1 or 2 substituents which are lower alkyl, halogen, alkylsulfonyl and/or arylsulfonyl; which comprises providing an oxazoline of the structure ##STR27## wherein m, n, R.sup.1 and R.sup.2 are as defined above, treating the oxazoline with an oxidizing agent which is cupric bromide or ferric bromide, a base which is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), and a non-hydride donor amine which does not have an .alpha.H or which will not easily lose an H at the .alpha. carbon under oxidation conditions and therefore will not undergo oxidation, to convert said oxazoline to an oxazole of the structure ##STR28## recovering the oxazole, and hydrolyzing the oxazole to the acid of the structure ##STR29##
- 20. The method as defined in claim 19 wherein the non-hydride donor amine is hexamethylenetetraamine (HMTA).
- 21. The method as defined in claim 19 wherein R.sup.1 is hydrogen, R.sup.2 is pentyl, m is 1 and n is 2.
- 22. The method as defined in claim 19 wherein the oxazoline has the structure ##STR30##
- 23. The method as defined in claim 19 wherein the oxidizing agent is cupric bromide, the base is DBU, and the non-hydride donor amine is HMTA.
- 24. The method as defined in claim 19 wherein a single charge of cupric bromide, DBU and non-hydride donor amine HMTA is employed.
- 25. The method as defined in claim 20 wherein a double charge of cupric bromide, DBU and non-hydride donor amine HMTA is employed.
- 26. The method as defined in claim 24 wherein each of the reactants of the single charge is employed in an amount to provide about 4 molar equivalents of each to each molar equivalent of oxazoline.
- 27. The method as defined in claim 26 wherein preparation of the oxazole ester is carried out for a period of from about 4 to about 6 hours.
REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of U.S. application Ser. No. 900,384, filed Jun. 18, 1992, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5100889 |
Misra et al. |
Mar 1992 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0476994 |
Mar 1992 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Misra et al., "Thromboxane Receptor Antagonist BMS-180291: A New Pre-Clinical Lead," Bioorganic and Medicinal Chemistry, vol. 2, No. 1, pp. 73-76, 1992. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
900384 |
Jun 1992 |
|